Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA4 | P22748 | 3/20 | 0.38 |
| ▸ | CA6 | P23280 | 3/20 | 0.38 |
| ▸ | CA5A | P35218 | 3/20 | 0.38 |
| ▸ | CA7 | P43166 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.38 |
| ▸ | CA3 | P07451 | 2/20 | 0.38 |
| ▸ | F13A1 | P00488 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12319688 | 1.00 | CYP2C19 (0.48) | CYP2C19CYP1A2MEN1KMT2ATSHR | |
| SCHEMBL25566471 | 0.97 | TSHR (0.45) | CYP2C19CYP1A2MEN1KMT2ATSHR | |
| SCHEMBL25565749 | 0.97 | CYP2C19 (0.45) | CYP2C19CYP1A2MEN1KMT2ATSHR | |
| SCHEMBL26107079 | 0.94 | CYP2C19 (0.43) | CYP2C19CYP1A2MEN1KMT2ATSHR | |
| SCHEMBL25566216 | 0.92 | CYP2C19 (0.41) | CYP2C19CYP1A2MEN1KMT2ATSHR | |
| SCHEMBL24013256 | 0.90 | TSHR (0.62) | CYP2C19CYP1A2MEN1KMT2ATSHR | |
| SCHEMBL18788095 | 0.90 | TSHR (0.48) | CYP2C19CYP1A2MEN1KMT2ATSHR | |
| SCHEMBL12323375 | 0.90 | CYP2C19 (0.40) | CYP2C19CYP1A2MEN1KMT2ATSHR | |
| SCHEMBL20738397 | 0.90 | CYP2C19 (0.40) | CYP2C19CYP1A2MEN1KMT2ATSHR | |
| SCHEMBL23739843 | 0.90 | CYP2C19 (0.40) | CYP2C19CYP1A2MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149562-A1 | CARRIERS FOR EFFICIENT NUCLEIC ACID DELIVERY | TIBA BIOTECH LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-11584933-B2 | RNA interference in ocular indications | PHIO PHARMACEUTICALS CORP. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230002766-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES TARGETING BROMODOMAIN CONTAINING PROTEIN 4 (BRD4) FOR IMMUNOTHERAPY | PHIO PHARMACEUTICALS CORP. (US) | 2023-01-05 | — | — | US | disclosed |
| US-20210348169-A1 | METHODS FOR TREATING AGING AND SKIN DISORDERS USING NUCLEIC ACIDS TARGETING TYR OR MMP1 | PHIO PHARMACEUTICALS CORP. (US) | 2021-11-11 | — | — | US | disclosed |
| US-11021707-B2 | Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA | PHIO PHARMACEUTICALS CORP. (US) | 2021-06-01 | — | — | US | disclosed |
| US-11001845-B2 | Nucleic acid molecules targeting superoxide dismutase 1 (SOD1) | PHIO PHARMACEUTICALS CORP. (US) | 2021-05-11 | — | — | US | disclosed |
| US-20210062195-A1 | RNA INTERFERENCE IN OCULAR INDICATIONS | PHIO PHARMACEUTICALS CORP. (US) | 2021-03-04 | — | — | US | disclosed |
| US-10913948-B2 | RNA interference in dermal and fibrotic indications | PHIO PHARMACEUTICALS CORP. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10808247-B2 | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach | PHIO PHARMACEUTICALS CORP. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10662430-B2 | RNA interference in ocular indications | PHIO PHARMACEUTICALS CORP. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190048341-A1 | REDUCED SIZE SELF-DELIVERING NUCLEIC ACID COMPOUNDS TARGETING LONG NON-CODING RNA | RXI PHARMACEUTICALS CORPORATION (US) | 2019-02-14 | — | — | US | disclosed |
| US-10184124-B2 | RNA interference in ocular indications | PHIO PHARMACEUTICALS CORP. (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180195072-A1 | NUCLEIC ACID MOLECULES TARGETING SUPEROXIDE DISMUTASE 1 (SOD1) | RXI PHARMACEUTICALS CORPORATION (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180195066-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS USING A SYNERGISTIC SMALL MOLECULE AND NUCLEIC ACIDS THERAPEUTIC APPROACH | RXI PHARMACEUTICALS CORPORATION (US) | 2018-07-12 | — | — | US | disclosed |
| US-9963702-B2 | RNA interference in dermal and fibrotic indications | RXI PHARMACEUTICALS CORPORATION (US) | 2018-05-08 | — | — | US | disclosed |
| US-20180030451-A1 | METHODS FOR TREATING AGING AND SKIN DISORDERS USING NUCLEIC ACIDS TARGETING TYR OR MMP1 | RXI PHARMACEUTICALS CORPORATION (US) | 2018-02-01 | — | — | US | disclosed |
| US-20170067056-A1 | RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS | RXI PHARMACEUTICALS CORPORATION (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170051290-A1 | METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES | RXI PHARMACEUTICALS CORPORATION (US) | 2017-02-23 | — | — | US | disclosed |
| WO-2011119887-A1 | RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS | RXI PHARMACEUTICALS CORPORATION (US) | 2011-09-29 | — | — | WO | disclosed |
| US-4442305-A | FOR USE IN CITRO OR IN VIVO | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 1984-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180195066-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS USING A SYNERGISTIC SMALL MOLECULE AND NUCLEIC ACIDS THERAPEUTIC APPROACH | SOD1, POLRMT, SMN1; SMN2 | CYP2C19 4885/4885CYP1A2 4860/4885MEN1 4147/4885 |
| US-11021707-B2 | Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA | SNRPA, SNRPE, NSUN3 | CYP2C19 4882/4885CYP1A2 4878/4885MEN1 1987/4885 |
| US-11584933-B2 | RNA interference in ocular indications | RXRA, RXRB, RXRG | CYP2C19 4442/4885CYP1A2 4032/4885MEN1 4837/4885 |
| US-10808247-B2 | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach | SOD1, POLRMT, SMN1; SMN2 | CYP2C19 4885/4885CYP1A2 4860/4885MEN1 4147/4885 |
| US-20230002766-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES TARGETING BROMODOMAIN CONTAINING PROTEIN 4 (BRD4) FOR IMMUNOTHERAPY | BRD4, BRDT, BRPF3 | CYP2C19 4885/4885CYP1A2 4883/4885MEN1 3905/4885 |
| US-11001845-B2 | Nucleic acid molecules targeting superoxide dismutase 1 (SOD1) | SOD1, SOD3, POLRMT | CYP2C19 4876/4885CYP1A2 4809/4885MEN1 4540/4885 |
| US-20170051290-A1 | METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES | POLRMT, NSUN3, ELAVL1 | CYP2C19 4881/4885CYP1A2 4865/4885MEN1 1278/4885 |
| US-20180030451-A1 | METHODS FOR TREATING AGING AND SKIN DISORDERS USING NUCLEIC ACIDS TARGETING TYR OR MMP1 | MMP1, MMP3, MMP11 | CYP2C19 4841/4885CYP1A2 4667/4885MEN1 4561/4885 |
| US-20230149562-A1 | CARRIERS FOR EFFICIENT NUCLEIC ACID DELIVERY | POLN, TLR9, TSG101 | CYP2C19 4867/4885CYP1A2 4870/4885MEN1 2899/4885 |
| US-20210062195-A1 | RNA INTERFERENCE IN OCULAR INDICATIONS | RXRA, RXRB, RXRG | CYP2C19 4442/4885CYP1A2 4032/4885MEN1 4837/4885 |
| US-10184124-B2 | RNA interference in ocular indications | RXRA, RXRB, RXRG | CYP2C19 4442/4885CYP1A2 4032/4885MEN1 4837/4885 |
| US-20210348169-A1 | METHODS FOR TREATING AGING AND SKIN DISORDERS USING NUCLEIC ACIDS TARGETING TYR OR MMP1 | MMP1, MMP3, MMP11 | CYP2C19 4841/4885CYP1A2 4667/4885MEN1 4561/4885 |
| US-10662430-B2 | RNA interference in ocular indications | RXRA, RXRB, RXRG | CYP2C19 4442/4885CYP1A2 4032/4885MEN1 4837/4885 |
| US-20180195072-A1 | NUCLEIC ACID MOLECULES TARGETING SUPEROXIDE DISMUTASE 1 (SOD1) | SOD1, SOD3, POLRMT | CYP2C19 4876/4885CYP1A2 4809/4885MEN1 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.